Barclays Maintains an 'Overweight' Rating on Amylin Pharmaceuticals (AMLN); TRx Share Continues to Increase Byetta Losing Share in GLPs

Barclays maintains an 'Overweight' rating on Amylin Pharmaceuticals (Nasdaq: AMLN), price target $29.

Barclays analys says,"IMS Health prescription data reported this morning suggests flat scrips sequentially for GLP-1 TRx and NRx, Byetta TRx and NRx, and Victoza NRx with an increase in Victoza TRx. Byetta market share within the GLP-1 category continued its decreasing trend while TRx share for GLP-1 drugs in the diabetes category continued to increase."

Shares are currently trading at $20.67, +0.23 (1.13%) and have gained over 50% in the past 12 months.

To see all the upgrades/downgrades on shares of AMLN, visit our Analyst Ratings page.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Nomura Securities Maintains a 'Buy' on Lowe's (LOW); Review of Q1
• Goldman Sachs Defends J.P. Morgan (JPM); 'Down But Not Out'
• Compass Point Maintains a 'Neutral' on PNC Financial (PNC); RBC Addition Positive Offset By Increased Competition in C&I Lending

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter